About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ: CMMB), is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases.

Chemomab is making great strides with its novel CM-101 proprietary platform, which hinders the fundamental function of the soluble chemokine CCL24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders.

CM-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets CCL24. Chemomab has shown that CM-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action.

Chemomab is actively advancing CM-101 into phase 2 studies to treat patients with liver fibrosis (Primary Sclerosing Cholangitis) and patients suffering from skin and lung fibrosis (Systemic Sclerosis).